The Castleman Disease Collaborative Network is set to have its best showing yet at the American Society of Hematology’s Annual Meeting and Exposition, the premier event of the global hematology community. Each year, ASH’s annual meeting brings together thousands of researchers, physicians, and educators from all over the world, including many of the world’s foremost experts in Castleman disease. As a result, the ASH annual meeting is an incredible opportunity to bring together the CDCN’s global network of physicians and researchers to inform the wider hematology community about cutting edge research on Castleman disease.

Cutting edge research and education

This year, the ASH Annual Meeting is being held in San Diego from December 1-4 and will have more presentations and programming dedicated to Castleman disease than in any prior year; a whopping total of 9 research projects related to Castleman disease will be presented during the meetings and poster sessions. All 9 projects involved members of the CDCN, with 5 of the projects funded directly by the CDCN. Asked about this year’s research progress, Dr. David Fajgenbaum, Executive Director of the CDCN, said:

“There are more Castleman disease related presentations at ASH than ever before and that comes down to the hard work of the CDCN community. From the gracious donors that supported our research grants to the patients battling Castleman disease that generously donated tissue samples, this year’s impressive showing is a testament to our community.”

In addition to disseminating cutting edge research, the ASH annual meeting also serves as an opportunity to teach best practices in Castleman disease diagnosis and treatment to practicing hematologists from around the world. This year, Dr. Fajgenbaum will be presenting about Castleman disease during two dedicated education sessions which will provide a forum to spread the recently published treatment guidelines for idiopathic multicentric Castleman disease. See the full iMCD treatment guidelines here.

CDCN Annual Working Dinner

This year’s ASH Annual Meeting will also serve as the backdrop for the CDCN’s 7th Annual “Accelerating Research and Treatments for Castleman Disease” Working Dinner Meeting. The meeting will be held on Saturday, December 1 and will include over 70 leading Castleman disease physicians and researchers. The dinner will serve as an opportunity to review new research, discuss challenges and issues related to patient care, and set the CDCN’s research plan for 2019. Speaking about the importance of the CDCN’s working dinner, Dr. Fajgenbaum said:

 “It serves as an opportunity for the CDCN’s network of physicians and researchers to come together, discuss the past year’s progress, and set our goals for next year. Looking back to our first meeting in 2012, the progress has been striking. This year is shaping up to be our best yet.”


For a full list of Castleman disease related projects being presented this year, please see below. 


 1. Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease - Dustin Shilling, PhD, Jason R Ruth, PhD, Christopher Sheild Nabel, MD, PhD, Sheila K Pierson, MS, Mary Guilfoyle, MS, Craig Tendler, MD, Manjula P Reddy, MS, MSc, Michael Weinblatt, MD, Nancy Shadick, MD, MPH, Mark Bower, MD, Alessia Dalla Pria, MD, Yasufumi Masaki, MD, PhD, Philip Beineke, MS, Sofija Miljovska, MS, Laura Katz, MA, Sushila Shenoy, PhD, Ana B Oromendia, PhD, Jason Mezey, PhD, Jeff Wiser, MS, Jef Benbanaste, MBA, David Lee, MA, Alexander Fosså, MD, PhD, Frits van Rhee, MD, PhD and David C Fajgenbaum, MD, MBA, MSc

2. Pilot Study of Tocilizumab in Patients with HIV and Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease - Ramya Ramaswami, MBBS, MPH, Kathryn Lurain, MD, MPH, Anaida Widell, Mark N. Polizzotto, Priscila H. Goncalves, MD, Matthew Lindsley, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD, MS and Robert Yarchoan, MD

3. Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients - Anna Wing, Wenzhao Meng, Ph.D., Gerald Wertheim, M.D., Ph.D, Dale Frank, M.D., Michele Paessler, D.O., Megan S. Lim, M.D., Ph.D., Eline T. Luning Prak, M.D., Ph.D., David C Fajgenbaum, MD, MBA, MSc and Vinodh Pillai, M.D., Ph.D

4. Oligoclonal Expansion of Cd8+ T Cells during Idiopathic Multicentric Castleman Disease Flares Suggests an Antigen Driven Process - Dustin Shilling, PhD, Jason E Stadanlick, PhD, Wenzhao Meng, Ph.D., Abhishek Rao, MS, Vera P Krymskaya, PhD, MBA, FCPP, Eline T. Luning Prak, M.D., Ph.D., Evgeniy B Eruslanov, PhD and David C Fajgenbaum, MD, MBA, MSc

5. Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center - Katie Stone, BS, Francisco Socola, MD, Amy Greenway1*, Samina Waheed, Kristen Carter, APRN, Diane Glendinning, APRN, Daisy Alapat, MD and Frits van Rhee, MD, PhD

6. Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization - Meera Mohan, MD, James C Meek, MD, Mary Elizabeth Meek, MD, Ralph Lynn Broadwater, MD, Katie Stone, BS, Amy Greenway, Daisy Alapat, MD and Frits van Rhee, MD, PhD

7. Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during Idiopathic Multicentric Castleman Disease Flare - Ruth-Anne Langan, BA, Dustin Shilling, PhD, Michael Gonzalez, PhD, Charlly Kao, PhD, Hakon Hakonarson, MD, PhD, Taku Kambayashi, MD, PhD and David C Fajgenbaum, MD, MBA, MSc

8. A Prospective Phase II Study of Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Idiopathic Multicentric Castleman's Disease - Lu Zhang, MD, Ai-lin Zhao, MD, Jun Feng, MD, Xinxin Cao, MD, Yan Zhang, MD, Tienan Zhu, MD, Minghui Duan, MD, Daobin Zhou, MD and Jian Li, MD

9. Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome - Dustin Shilling, PhD, Dale M Kobrin, BA and David C Fajgenbaum, MD, MBA, MSc


There are no comments yet.

Leave a Comment